株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

自閉症スペクトラム障害 (ASD) の診断と治療:世界市場

Diagnostics and Therapeutics for Autism Spectrum Disorders: Global Markets

発行 BCC Research 商品コード 325766
出版日 ページ情報 英文 162 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.52円で換算しております。
Back to Top
自閉症スペクトラム障害 (ASD) の診断と治療:世界市場 Diagnostics and Therapeutics for Autism Spectrum Disorders: Global Markets
出版日: 2015年03月11日 ページ情報: 英文 162 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の自閉症スペクトラム障害 (ASD) 市場規模は2013年に3億4,620万米ドル、2014年には3億6,090万米ドルとなりました。同市場は今後2.7%のCAGRで拡大し、2019年までに4億1,270万米ドルに達すると予測されています。

当レポートは、世界の自閉症スペクトラム障害 (ASD) 治療・診断市場について調査し、世界・地域市場の概要、実績データ・推計およびCAGR予測を含めた世界市場動向の分析、種類・疫学・症状・病因・病態生理学関する情報、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 自閉症の定義
  • 自閉症の背景
  • なぜ自閉症は「スペクトラム障害」なのか?
  • ASDの中核症状
  • ASDの非中核症状
  • ASDの病因
  • ASDの疫学
  • ASDの診断・治療基準
  • ASDの薬物療法

第4章 規制情勢

第5章 世界市場

  • 治療市場
    • 概要
    • 世界のASD治療市場:ラベル情報別
      • ASDラベル医薬品
      • オフラベル医薬品
    • 世界のASD治療市場:治療クラス別
      • 抗精神病薬
      • 精神刺激薬
      • 抗鬱薬
      • 抗てんかん薬
      • 降圧剤
      • 睡眠薬
      • その他
      • 新しい治療クラス
    • 世界のASD治療市場:症状別
      • 興奮性
      • ADHD
      • 攻撃性
      • 発作
      • 不安神経症・気分障害
      • 睡眠障害
      • 錐体外路症状
      • ASD (中核症状)
    • 世界のASD治療市場:作用機序別
      • ドーパミン・セロトニン経路標的薬
      • アドレナリン受容体標的薬
      • GABAA経路標的薬
      • その他作用機序の治療薬
      • 新たな作用機序の治療薬
    • 世界のASD治療:企業別
  • 世界のASD診断市場
    • 概要
    • 技術
    • 市場
    • 結論
  • 世界のASD市場促進因子・阻害因子
    • 促進因子
    • 阻害因子
    • 世界のASD市場:地域別

第6章 北米市場

  • 治療市場
    • 概要
    • 北米におけるASD治療市場:治療クラス別
    • 北米のASD診断市場
    • 北米のASD市場:国別

第7章 欧州市場

第8章 日本市場

第9章 パイプライン評価

  • 概要
  • 戦略的パイプライン評価
  • パイプライン分析:開発段階別
  • パイプライン:作用機序別
  • 臨床パイプライン:症状別
  • 臨床パイプライン:ASDの表現型別
  • 技術動向・分析のフレームワーク
  • 最も有望な薬剤のプロファイル
    • NNZ-2566
    • CM-AT
    • RG-7314
    • LATUDA

第10章 診断技術:近年の発展

  • 市場参入製品
    • ARISK2
    • NEXTSTEP
    • COMBISNP
    • DEVACT AND DEVSEEK
  • 市場参入製品の比較評価

第11章 企業プロファイル

  • 治療薬
  • 診断

図表リスト

目次
Product Code: HLC181A

REPORT HIGHLIGHTS

The global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%.

This report provides:

  • An overview of the regional and global markets for Autism Spectrum Disorder (ASD) therapies and diagnostics.
  • Analyses of global market trends, with data from 2013, 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • An overview of ASDs including types, epidemiology, symptoms, and causes and pathophysiology.
  • Coverage of approved therapies and tolerated off-label alternative treatments for ASD.
  • In-depth analysis of the ASD therapies market dynamics, specifically growth drivers, inhibitors, and opportunities.
  • A relevant patent analysis including patents nearing expiration, and recently issued patents.
  • Comprehensive profiles of major players in the field.

SCOPE OF THE STUDY

The scope of this study encompasses the global and regional markets for therapeutic and diagnostic technologies of ASD. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market share. Issues discussed include the major drug profiles, technological features and trends. The global markets for the ASD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Spain, Italy and Japan. The markets of the rest of the world are not reported due to their economic insignificance for this report.

ANALYST'S CREDENTIALS

This report was authored by Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. The analyst possesses extensive pharmaceutical research and development experience through participating projects in various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama due to his high quality of work and excellence in the fields of research.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • INFORMATION SOURCES AND TECHNOLOGY BENCHMARKING
  • FORECASTING METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL ASD MARKET, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL ASD MARKET, 2013-2019 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • DEFINITION OF AUTISM
  • BACKGROUND OF AUTISM
  • WHY IS AUTISM A 'SPECTRUM' DISORDER?
  • CORE SYMPTOMS OF ASD
  • NON-CORE SYMPTOMS OF ASD
  • ETIOLOGY OF ASD
    • GENETIC FACTORS
    • NEUROCHEMICAL FACTORS
    • ENVIRONMENTAL FACTORS
  • EPIDEMIOLOGY OF ASD
    • SEX RATIO
    • AGE
    • PREVALENCE
    • HERITABILITY
    • COMORBIDITY
      • TABLE 1: ASD-ASSOCIATED COMORBIDITIES AND THEIR PREVALENCE RATES
    • SUBTYPE
    • SEVERITY
  • STANDARDS FOR THE DIAGNOSIS AND TREATMENT OF ASD
    • SCREENING AND DIAGNOSIS OF ASD
  • PHARMACEUTICAL TREATMENT OF ASD
    • ASD-LABELED PHARMACEUTICALS
    • OFF-LABEL PHARMACEUTICALS
      • Antipsychotics
      • Psychostimulants
      • Antidepressants
      • Antiepileptic Drugs
      • Antihypertensives
      • Sleep Medications
      • Antianxiety Medications
    • OPPORTUNITIES IN PHARMACEUTICAL DEVELOPMENT

CHAPTER 4 - REGULATORY LANDSCAPE

  • TABLE 2: LIST OF PEDIATRIC LABEL REVISIONS FOR APPROVED AND OFF-LABEL DRUGS USED ON ASD POPULATIONS
  • TABLE 3: LIST OF ISSUED SAFETY WARNINGS FOR APPROVED AND OFF-LABEL PHARMACEUTICALS USED ON ASD POPULATIONS
  • TABLE 4: LIST OF DRUGS UNDER PEDIATRIC INVESTIGATION

CHAPTER 5 - GLOBAL MARKETS

  • TABLE 5: GLOBAL ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
  • FIGURE 1: GLOBAL ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
  • THERAPEUTICS MARKET
    • OVERVIEW
    • GLOBAL ASD THERAPEUTICS MARKET BY LABEL INFORMATION
      • TABLE 6: GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 2: GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, 2013-2019 ($ MILLIONS)
      • ASD-labeled Pharmaceuticals
      • Off-label Pharmaceuticals
    • GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS
      • TABLE 7: GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ MILLIONS)
      • FIGURE 3: GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ MILLIONS)
      • Antipsychotics
        • TABLE 8: GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 4: GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
      • Psychostimulants
        • TABLE 9: GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 5: GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
      • Antidepressants
        • TABLE 10: GLOBAL ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 6: GLOBAL ANTIDEPRESSANTS MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
      • Antiepileptics
        • TABLE 11: GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 7: GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
      • Antihypertensives
        • TABLE 12: GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 8: GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
      • Sleep Medications
        • TABLE 13: GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 9: GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
      • Other
        • TABLE 14: GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 10: GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
      • Novel Therapeutic Classes
        • TABLE 15: GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 11: GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • GLOBAL ASD THERAPEUTICS MARKET BY INDICATION
      • TABLE 16: GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 12: GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, 2013-2019 ($ MILLIONS)
      • Irritability
        • TABLE 17: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, THROUGH 2019 ($ MILLIONS)
        • FIGURE 13: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, 2013-2019 ($ MILLIONS)
    • ADHD
      • TABLE 18: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, THROUGH 2019 ($ MILLIONS)
      • FIGURE 14: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, 2013-2019 ($ MILLIONS)
      • Aggression
        • TABLE 19: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 15: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, 2013-2019 ($ MILLIONS)
      • Seizures
        • TABLE 20: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, THROUGH 2019 ($ MILLIONS)
        • FIGURE 16: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, 2013-2019 ($ MILLIONS)
      • Anxiety and Mood Disorders
        • TABLE 21: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 17: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, 2013-2019 ($ MILLIONS)
      • Sleeping Disorders
        • TABLE 22: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 18: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, 2013-2019 ($ MILLIONS)
      • Extrapyramidal Symptoms
        • TABLE 23: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 19: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, 2013-2019 ($ MILLIONS)
      • ASD (Core Symptoms)
        • TABLE 24: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), THROUGH 2019 ($ MILLIONS)
        • FIGURE 20: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), 2013-2019 ($ MILLIONS)
    • GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION
      • TABLE 25: GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 21: GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, 2013-2019 ($ MILLIONS)
      • Dopamine and Serotonin Pathway Targeting Drugs
        • TABLE 26: GLOBAL ASD THERAPEUTICS MARKET FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 22: GLOBAL ASD THERAPEUTICS FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, 2013-2019 ($ MILLIONS)
      • Adrenergic Receptor Targeting Drugs
        • TABLE 27: GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 23: GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2013-2019 ($ MILLIONS)
      • GABAA Pathway Targeting Drugs
        • TABLE 28: GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 24: GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, 2013-2019 ($ MILLIONS)
      • Drugs with Other Mechanisms of Action
        • TABLE 29: GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, THROUGH 2019 ($MILLIONS)
        • FIGURE 25: GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, 2013-2019 ($ MILLIONS)
      • Drugs with Novel Mechanisms of Action
        • TABLE 30: GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, THROUGH 2019 ($MILLIONS)
        • FIGURE 26: GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, 2013-2019 ($ MILLIONS)
    • GLOBAL ASD THERAPEUTICS BY COMPANY
      • FIGURE 27: GLOBAL ASD THERAPEUTICS MARKET BY COMPANY, FOR 2014 (%)
  • GLOBAL ASD DIAGNOSTICS MARKET
    • OVERVIEW
      • TABLE 31: GLOBAL ASD DIAGNOSTICS MARKET, THROUGH 2019 ($ MILLIONS)
      • FIGURE 28: GLOBAL ASD DIAGNOSTICS MARKET, 2013-2019 ($ MILLIONS)
  • TECHNOLOGIES
    • MARKET
      • TABLE 32: GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, THROUGH 2019 ($ MILLIONS)
      • FIGURE 29: GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, 2013-2019 ($ MILLIONS)
      • Low Imbursement Group
        • TABLE 33: GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
        • FIGURE 30: GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
      • Moderate Imbursement Group
        • TABLE 34: GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
        • FIGURE 31: GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
      • High Imbursement Group
        • TABLE 35: GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
        • FIGURE 32: GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
    • CONCLUDING REMARKS
  • GLOBAL ASD MARKET DRIVERS AND RESTRAINTS
    • DRIVERS
    • RESTRAINTS
    • GLOBAL ASD MARKETS BY GEOGRAPHICAL REGION
      • TABLE 36: GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 33: GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, 2013-2019 ($ MILLIONS)

CHAPTER 6 - MARKETS IN NORTH AMERICA

  • FIGURE 34: ASD PREVALENCE RATES IN NORTH AMERICA, 2000-2013 (PER 10,000 PEOPLE)
  • TABLE 37: NORTH AMERICAN ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
  • FIGURE 35: NORTH AMERICAN ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
  • THERAPEUTICS MARKET
    • OVERVIEW
      • TABLE 38: NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
      • FIGURE 36: NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
    • ASD THERAPEUTICS MARKETS IN NORTH AMERICA BY THERAPEUTIC CLASS
      • TABLE 39: NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
      • FIGURE 37: NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ THOUSANDS)
      • Antipsychotics
        • TABLE 40: NORTH AMERICAN ANTIPSYCHOTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 38: NORTH AMERICAN ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Psychostimulants
        • TABLE 41: NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 39: NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Antidepressants
        • TABLE 42: NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 40: NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Antiepileptics
        • TABLE 43: NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 41: NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Antihypertensives
        • TABLE 44: NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 42: NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Sleep Medications
        • TABLE 45: NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 43: NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Other
        • TABLE 46: NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 44: NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Novel
        • TABLE 47: NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 45: NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
  • NORTH AMERICAN ASD DIAGNOSTICS MARKETS
    • OVERVIEW
    • MARKET
    • FORECAST
      • TABLE 48: NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
      • FIGURE 46: NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
  • NORTH AMERICAN ASD MARKET BY COUNTRY
    • TABLE 49: NORTH AMERICAN ASD MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
    • FIGURE 47: NORTH AMERICAN ASD MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)

CHAPTER 7 - MARKETS IN EUROPE

  • FIGURE 48: ASD COMBINED PREVALENCE RATES IN EU5 COUNTRIES, 2000 TO 2011 (PER 10,000 PEOPLE)
  • TABLE 50: EU5 ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
  • FIGURE 49: EU5 ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
  • THERAPEUTICS MARKET
    • OVERVIEW
      • TABLE 51: EU5 ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
      • FIGURE 50: EU5 ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
    • ASD THERAPEUTICS MARKETS IN EU5 BY THERAPEUTIC CLASS
      • TABLE 52: EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
      • FIGURE 51: EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ THOUSANDS)
      • Antipsychotics
        • TABLE 53: EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 52: EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Psychostimulants
        • TABLE 54: EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 53: EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Antidepressants
        • TABLE 55: EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 54: EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Antiepileptics
        • TABLE 56: EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 55: EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Antihypertensives
        • TABLE 57: EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 56: EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Sleep Medications
        • TABLE 58: EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 57: EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
      • Other
        • TABLE 59: EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 58: EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
  • EU5 ASD DIAGNOSTICS MARKETS
    • OVERVIEW
    • MARKET
    • FORECAST
      • TABLE 60: EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
      • FIGURE 59: EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
  • EU5 ASD MARKET BY COUNTRY
    • TABLE 61: EU5 ASD MARKETS BY COUNTRY, THROUGH 2019 ($ MILLIONS)
    • FIGURE 60: EU5 ASD MARKETS BY COUNTRY, 2013-2019 ($ MILLIONS)

CHAPTER 8 - MARKETS IN JAPAN

  • FIGURE 61: ASD PREVALENCE RATES IN JAPAN, 2000-2013 (PER 10,000 PEOPLE)
  • TABLE 62: JAPANESE ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
  • FIGURE 62: JAPANESE ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
  • THERAPEUTICS MARKET
    • OVERVIEW
    • ASD THERAPEUTICS MARKET IN JAPAN BY THERAPEUTIC CLASS
      • TABLE 63: JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
      • FIGURE 63: JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ THOUSANDS)
      • Antipsychotics
        • TABLE 64: JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 64: JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
      • Psychostimulants
        • TABLE 65: JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 65: JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
      • Antidepressants
        • TABLE 66: JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 66: JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
      • Antiepileptics
        • TABLE 67: JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 67: JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
      • Antihypertensives
        • TABLE 68: JAPANESE ANTIHYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 68: JAPANESE ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
      • Sleep Medications
        • TABLE 69: JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 69: JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
      • Other
        • TABLE 70: JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
        • FIGURE 70: JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
  • JAPANESE ASD DIAGNOSTICS MARKET
    • OVERVIEW
    • MARKET
    • FORECAST
      • TABLE 71: JAPANESE ASD DIAGNOSTICS MARKET, THROUGH 2019 ($ MILLIONS)
      • FIGURE 71: JAPANESE ASD DIAGNOSTICS MARKET, 2013-2019 ($ MILLIONS)

CHAPTER 9 - PIPELINE ASSESSMENT

  • OVERVIEW
  • STRATEGIC PIPELINE ASSESSMENT
  • PIPELINE ANALYSIS BY PHASE OF DEVELOPMENT
    • PHASE III CLINICAL PIPELINE
      • TABLE 72: NUMBER OF PHASE III CLINICAL TRIALS BY COUNTRY, 2014
    • PHASE II CLINICAL PIPELINE
      • TABLE 73: NUMBER OF PHASE II CLINICAL TRIALS BY COUNTRY, 2014
    • PHASE I CLINICAL PIPELINE
      • TABLE 74: NUMBER OF PHASE I CLINICAL TRIALS BY COUNTRY, 2014
    • PIPELINE BY MECHANISM OF ACTION
      • TABLE 75: NUMBER OF CLINICAL TRIALS BY MECHANISM OF ACTION, 2014
    • CLINICAL PIPELINE BY INDICATION
      • TABLE 76: NUMBER OF CLINICAL TRIALS BY INDICATION, 2014
    • CLINICAL PIPELINE BY PHENOTYPES OF ASD
      • TABLE 77: NUMBER OF CLINICAL TRIALS BY PHENOTYPES OF ASD BY COUNTRY, 2014
  • TECHNOLOGICAL TRENDS AND ANALYTICAL FRAMEWORK
  • MOST PROSPECTIVE DRUG PROFILES
    • NNZ-2566
      • Overview
      • Efficacy
      • Safety
      • Clinical Study Details
        • Phase I Clinical Trial
        • Phase II Clinical Trial
          • TABLE 78: TARGET DRUG PROFILE: NNZ-2566
  • CM-AT
    • Overview
      • Efficacy
      • Safety
      • Clinical Trial Details
        • Phase III Clinical Trials
          • TABLE 79: TARGET DRUG PROFILE: CM-AT
  • RG-7314
    • Overview
      • Efficacy
      • Safety
      • Clinical Trial Details
        • Phase II Clinical Trials
        • Phase I Clinical Trials
          • TABLE 80: TARGET DRUG PROFILE: RG7314
  • LATUDA
    • Overview
      • Efficacy
      • Safety
      • Clinical Trial Details
        • Phase III Clinical Trials
          • TABLE 81: TARGET DRUG PROFILE: LATUDA

CHAPTER 10 - DIAGNOSTIC TECHNOLOGIES: RECENT DEVELOPMENTS

  • MARKET-ENTRY PRODUCTS
    • ARISK2
      • Description
      • Technology Value Appraisal
        • Technology Validity and Utility
        • Innovation and Reimbursement Strategy
        • Cost/comparative Effectiveness
    • NEXTSTEP
      • Description
      • Technology Value Appraisal
        • Technology Validity and Utility
        • Innovation and Reimbursement Strategy
        • Cost/Comparative Effectiveness
    • COMBISNP
      • Description
      • Technology Value Appraisal
        • Technology Validity and Utility
        • Innovation and Reimbursement Strategy
        • Cost/Comparative Effectiveness
    • DEVACT AND DEVSEEK
      • Description
      • Technology Value Appraisal
        • Technology Validity and Utility
        • Innovation and Reimbursement Strategy
        • Cost/Comparative Effectiveness
    • COMPARATIVE EVALUATION FOR MARKET-ENTRY PRODUCTS
      • TABLE 82: MARKET VALUE ESTIMATES OF FOUR MARKET-ENTRY ASD DIAGNOSTIC PRODUCTS IN THE PIPELINE
      • SDX-002
        • Developmental Phase
        • Technology Value Appraisal

CHAPTER 11 - COMPANY PROFILES

  • THERAPEUTICS
    • ABBVIE INC.
    • ALCOBRA LTD.
    • APOTEX INC.
    • ASTRAZENECA PLC.
    • AUTISM THERAPEUTICS
    • AVANIR PHARMACEUTICALS INC.
    • BOEHRINGER INGELHEIM
    • CORONADO BIOSCIENCES, INC.
    • CUREMARK LLC
    • ELI LILLY & CO.
    • F. HOFFMANN-LA ROCHE AG
    • FOREST LABORATORIES INC.
    • GLAXOSMITHKLINE
    • JANSSEN PHARMACEUTICALS INC.
    • MALLINCKRODT PHARMACEUTICALS
    • MARINUS PHARMACEUTICALS INC.
    • NEUREN PHARMACEUTICALS LTD.
    • NOVARTIS PHARMA SERVICES AG
    • OTSUKA PHARMACEUTICALS
    • PFIZER INC.
    • PHARMACIA & UPJOHN LLC
    • SUNOVION PHARMACEUTICALS INC.
  • DIAGNOSTICS
    • AMBRY GENETICS
    • ATHENA DIAGNOSTICS
    • COMBIMATRIX CORP.
    • COURTAGEN LIFE SCIENCES INC.
    • GENEDX
    • INTEGRAGEN
    • LINEAGEN INC.
    • SYNAPDX
    • TRANSGENOMIC INC.

LIST OF TABLES

  • SUMMARY TABLE GLOBAL ASD MARKET, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: ASD-ASSOCIATED COMORBIDITIES AND THEIR PREVALENCE RATES
    • TABLE 2: LIST OF PEDIATRIC LABEL REVISIONS FOR APPROVED AND OFF-LABEL DRUGS USED ON ASD POPULATIONS
    • TABLE 3: LIST OF ISSUED SAFETY WARNINGS FOR APPROVED AND OFF-LABEL PHARMACEUTICALS USED ON ASD POPULATIONS
    • TABLE 4: LIST OF DRUGS UNDER PEDIATRIC INVESTIGATION
    • TABLE 5: GLOBAL ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 6: GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 7: GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ MILLIONS)
    • TABLE 8: GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
    • TABLE 9: GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
    • TABLE 10: GLOBAL ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
    • TABLE 11: GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
    • TABLE 12: GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
    • TABLE 13: GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
    • TABLE 14: GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
    • TABLE 15: GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ MILLIONS)
    • TABLE 16: GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 17: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, THROUGH 2019 ($ MILLIONS)
    • TABLE 18: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, THROUGH 2019 ($ MILLIONS)
    • TABLE 19: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, THROUGH 2019 ($ MILLIONS)
    • TABLE 20: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, THROUGH 2019 ($ MILLIONS)
    • TABLE 21: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, THROUGH 2019 ($ MILLIONS)
    • TABLE 22: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, THROUGH 2019 ($ MILLIONS)
    • TABLE 23: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, THROUGH 2019 ($ MILLIONS)
    • TABLE 24: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), THROUGH 2019 ($ MILLIONS)
    • TABLE 25: GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, THROUGH 2019 ($ MILLIONS)
    • TABLE 26: GLOBAL ASD THERAPEUTICS MARKET FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
    • TABLE 27: GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
    • TABLE 28: GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, THROUGH 2019 ($ MILLIONS)
    • TABLE 29: GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, THROUGH 2019 ($MILLIONS)
    • TABLE 30: GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, THROUGH 2019 ($MILLIONS)
    • TABLE 31: GLOBAL ASD DIAGNOSTICS MARKET, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, THROUGH 2019 ($ MILLIONS)
    • TABLE 33: GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
    • TABLE 34: GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, THROUGH 2019 ($ MILLIONS)
    • TABLE 36: GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 37: NORTH AMERICAN ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 38: NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
    • TABLE 39: NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 40: NORTH AMERICAN ANTIPSYCHOTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 41: NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 42: NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 43: NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 44: NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 45: NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 46: NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 47: NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 48: NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
    • TABLE 49: NORTH AMERICAN ASD MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
    • TABLE 50: EU5 ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 51: EU5 ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
    • TABLE 52: EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 53: EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 54: EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 55: EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 56: EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 57: EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 58: EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 59: EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 ($ THOUSANDS)
    • TABLE 60: EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 ($ MILLIONS)
    • TABLE 61: EU5 ASD MARKETS BY COUNTRY, THROUGH 2019 ($ MILLIONS)
    • TABLE 62: JAPANESE ASD MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 63: JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 64: JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 65: JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 66: JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 67: JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 68: JAPANESE ANTIHYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 69: JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 70: JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 ($ THOUSANDS)
    • TABLE 71: JAPANESE ASD DIAGNOSTICS MARKET, THROUGH 2019 ($ MILLIONS)
    • TABLE 72: NUMBER OF PHASE III CLINICAL TRIALS BY COUNTRY, 2014
    • TABLE 73: NUMBER OF PHASE II CLINICAL TRIALS BY COUNTRY, 2014
    • TABLE 74: NUMBER OF PHASE I CLINICAL TRIALS BY COUNTRY, 2014
    • TABLE 75: NUMBER OF CLINICAL TRIALS BY MECHANISM OF ACTION, 2014
    • TABLE 76: NUMBER OF CLINICAL TRIALS BY INDICATION, 2014
    • TABLE 77: NUMBER OF CLINICAL TRIALS BY PHENOTYPES OF ASD BY COUNTRY, 2014
    • TABLE 78: TARGET DRUG PROFILE: NNZ-2566
    • TABLE 79: TARGET DRUG PROFILE: CM-AT
    • TABLE 80: TARGET DRUG PROFILE: RG7314
    • TABLE 81: TARGET DRUG PROFILE: LATUDA
    • TABLE 82: MARKET VALUE ESTIMATES OF FOUR MARKET-ENTRY ASD DIAGNOSTIC PRODUCTS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL ASD MARKET, 2013-2019 ($ MILLIONS)
    • FIGURE 1: GLOBAL ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
    • FIGURE 2: GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, 2013-2019 ($ MILLIONS)
    • FIGURE 3: GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ MILLIONS)
    • FIGURE 4: GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • FIGURE 5: GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • FIGURE 6: GLOBAL ANTIDEPRESSANTS MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • FIGURE 8: GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • FIGURE 9: GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • FIGURE 10: GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • FIGURE 11: GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, 2013-2019 ($ MILLIONS)
    • FIGURE 12: GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, 2013-2019 ($ MILLIONS)
    • FIGURE 13: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, 2013-2019 ($ MILLIONS)
    • FIGURE 14: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, 2013-2019 ($ MILLIONS)
    • FIGURE 15: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, 2013-2019 ($ MILLIONS)
    • FIGURE 16: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, 2013-2019 ($ MILLIONS)
    • FIGURE 17: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, 2013-2019 ($ MILLIONS)
    • FIGURE 18: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, 2013-2019 ($ MILLIONS)
    • FIGURE 19: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, 2013-2019 ($ MILLIONS)
    • FIGURE 20: GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), 2013-2019 ($ MILLIONS)
    • FIGURE 21: GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, 2013-2019 ($ MILLIONS)
    • FIGURE 22: GLOBAL ASD THERAPEUTICS FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, 2013-2019 ($ MILLIONS)
    • FIGURE 23: GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2013-2019 ($ MILLIONS)
    • FIGURE 24: GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, 2013-2019 ($ MILLIONS)
    • FIGURE 25: GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, 2013-2019 ($ MILLIONS)
    • FIGURE 26: GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, 2013-2019 ($ MILLIONS)
    • FIGURE 27: GLOBAL ASD THERAPEUTICS MARKET BY COMPANY, FOR 2014 (%)
    • FIGURE 28: GLOBAL ASD DIAGNOSTICS MARKET, 2013-2019 ($ MILLIONS)
    • FIGURE 29: GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, 2013-2019 ($ MILLIONS)
    • FIGURE 30: GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
    • FIGURE 31: GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
    • FIGURE 32: GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, 2013-2019 ($ MILLIONS)
    • FIGURE 33: GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, 2013-2019 ($ MILLIONS)
    • FIGURE 34: ASD PREVALENCE RATES IN NORTH AMERICA, 2000-2013 (PER 10,000 PEOPLE)
    • FIGURE 35: NORTH AMERICAN ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
    • FIGURE 36: NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
    • FIGURE 37: NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ THOUSANDS)
    • FIGURE 38: NORTH AMERICAN ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 39: NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 40: NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 41: NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 42: NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 43: NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 44: NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 45: NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 46: NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
    • FIGURE 47: NORTH AMERICAN ASD MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
    • FIGURE 48: ASD COMBINED PREVALENCE RATES IN EU5 COUNTRIES, 2000 TO 2011 (PER 10,000 PEOPLE)
    • FIGURE 49: EU5 ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
    • FIGURE 50: EU5 ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
    • FIGURE 51: EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ THOUSANDS)
    • FIGURE 52: EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 53: EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 54: EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 55: EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 56: EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 57: EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 58: EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 ($ THOUSANDS)
    • FIGURE 59: EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 ($ MILLIONS)
    • FIGURE 60: EU5 ASD MARKETS BY COUNTRY, 2013-2019 ($ MILLIONS)
    • FIGURE 61: ASD PREVALENCE RATES IN JAPAN, 2000-2013 (PER 10,000 PEOPLE)
    • FIGURE 62: JAPANESE ASD MARKET BY APPLICATION, 2013-2019 ($ MILLIONS)
    • FIGURE 63: JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 ($ THOUSANDS)
    • FIGURE 64: JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
    • FIGURE 65: JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
    • FIGURE 66: JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
    • FIGURE 67: JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
    • FIGURE 68: JAPANESE ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
    • FIGURE 69: JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
    • FIGURE 70: JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 ($ THOUSANDS)
    • FIGURE 71: JAPANESE ASD DIAGNOSTICS MARKET, 2013-2019 ($ MILLIONS)
Back to Top